TRT(SH:600085) Xin Lang Cai Jing·2026-02-06 01:30Core Insights - The Jilin Provincial Public Resource Trading Center has initiated a price verification for 48 drugs with significantly higher listed prices compared to retail channels, marking a significant step in addressing the issue of hospital prices exceeding those in pharmacies [2][14] - The price discrepancies range from 1.3 times to 5.2 times, with notable examples including the inhaled budesonide suspension showing a 5.2 times difference and the An Gong Niu Huang Wan from Shandong Hongjitang and Beijing Tongrentang exceeding 4 times [2][15] - This initiative reflects a broader trend in drug price governance, indicating a shift from centralized procurement to comprehensive price management across all channels by 2026 [2][9] Price Discrepancy Details - The inhaled budesonide suspension has a procurement price of 388.11 yuan per mg in medical institutions, while the retail price is only 75 yuan, resulting in a 5.2 times price difference [3][15] - An Gong Niu Huang Wan produced by Shandong Hongjitang has a procurement price of 434.9 yuan per unit, compared to a retail price of 99 yuan, leading to a 4.4 times difference [7] - The price verification process is based on the "mode price," which reflects the most frequently occurring price after excluding outliers, ensuring a fair assessment of market prices [7][8] Industry Context - The rapid development of retail pharmacies and online drug purchasing platforms has intensified price competition, yet procurement prices in medical institutions remain high, exacerbating the price gap [2][8] - The National Medical Insurance Administration's upcoming initiatives, including monitoring online drug prices, aim to address these discrepancies and enhance price transparency [8][9] - The Jilin province's actions are part of a larger national strategy to improve drug pricing systems, with expectations for similar initiatives to be adopted by other provinces in the near future [12][14]